Testing a new radioactive injection for advanced thyroid cancer

Plain-English translation of NCT06898437 on ClinicalTrials.gov ↗ · Source last updated April 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This early-stage trial is testing a new medication called for people with a type of advanced thyroid cancer that has stopped responding to radioactive iodine treatment or other standard drugs. The medication is a radioactive injection designed to target cancer cells. Researchers want to see whether this treatment can slow or shrink the cancer and whether it is safe to use.

Some people with advanced thyroid cancer stop responding to the standard treatments available today, leaving them with very few options. This trial exists to explore whether this new radioactive medication could offer hope to patients who have run out of other treatment choices.

Do you qualify?

You likely qualify if…

you are 18 years or older
you have been diagnosed with radioiodine-refractory differentiated thyroid cancer and either failed treatment with targeted therapy drugs or chose not to pursue standard treatment
your cancer cells test positive for a specific marker called FAP, confirmed by a special imaging scan
you are in generally good health with a life expectancy of at least 6 months
your blood counts, liver function, and kidney function are adequate based on recent blood tests
you have at least one measurable tumor that can be tracked on imaging scans

You likely don't qualify if…

you have brain metastases (cancer that has spread to your brain) that are causing symptoms or are not stable
you have been diagnosed with another type of cancer in the past 5 years
you have received other cancer treatments (chemotherapy, radiation, immunotherapy, or similar drugs) within the past 4 weeks
you have severe heart disease, recent heart surgery, or serious heart rhythm problems
you have received other radioactive cancer treatments within the past 6 months

What participation looks like

If you join this trial, you will receive the radioactive injection intravenously (through an IV in your vein) every 6 weeks for at least 2 cycles of treatment. Your doctors will monitor your tumor response with imaging scans and blood tests and watch carefully for any side effects. Depending on how well you respond and how well you tolerate the medication, you may be able to continue treatment for up to 6 cycles total (about 6 months).

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(1 site)

China

Peking Union Medical College Hospital, Beijing